ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027 MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announc

MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026. Presentation DetailsDate: Thursday, January 15th, 2026Time: 9:00 AM PT A webcast and replay of Oruka's presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About Oruka Therapeutics Oruka

MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. "As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka," said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. "Chris's expertise can bring tremendous value to the compan

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2b (EVERLAST-A and -B), and ORKA-002 Phase 2 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 ORKA-001 Phase 2a trial enrolling well with data expected 2H 2026 MENLO PARK, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Monday, November 10th, 2025Time: 9:00AM ET Stifel 2025 Healthcare ConferenceDate: Tuesday, November 11th, 2025Time: 4:40PM ET Jefferies Global Healthcare ConferenceDate: Tuesday, November 18th, 2025Time: 2:00PM GMT A webcast and replay of Oruka's presentation will be available on th

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka" or the "Company") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing was led by Viking Global Investors, and included participation from both new and existing investors, including Affinity Healthc

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable safety profile consistent with the IL-23p19 class EVERLAST-A Phase 2a trial enrollment ongoing with data expected 2H 2026 MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced interim data from

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported second quarter 2025 financial results and provided a corporate update. "We are very pleased to have initiated our EVERLAST-A study, and we expect nearl

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to be shared in an oral presentation at EADV in September MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the U.S. FDA cleared its investigational new drug (IND) application for its Phase 2a trial of ORKA-001 (the Company's long-acting anti-IL-23p19 antibody) in moderate-

MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer. Ms. Sandler, who joined Oruka in 2024 as SVP of Operations, brings over 20 years of biopharmaceutical leadership experience across clinical operations, development strategy, and quality. She has played a pivotal role in progressing Oruka's programs from preclinical stages into clinical trials with speed and precision. "I've had the privilege

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

SCHEDULE 13G - Oruka Therapeutics, Inc. (0000907654) (Subject)

144 - Oruka Therapeutics, Inc. (0000907654) (Subject)

8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

SCHEDULE 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)

424B3 - Oruka Therapeutics, Inc. (0000907654) (Filer)

424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)

S-3/A - Oruka Therapeutics, Inc. (0000907654) (Filer)

S-3/A - Oruka Therapeutics, Inc. (0000907654) (Filer)

S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)

Piper Sandler initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $75.00

Jefferies initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00

Guggenheim initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $60.00

Barclays initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $48.00

BTIG Research initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $44.00

Wolfe Research initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $20.00

Stifel initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $49.00

H.C. Wainwright initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00

Leerink Partners initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $44.00

TD Cowen initiated coverage of Oruka Therapeutics with a rating of Buy

MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. "As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka," said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. "Chris's expertise can bring tremendous value to the compan

SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G - Oruka Therapeutics, Inc. (0000907654) (Subject)